metformin has been researched along with Erythroderma, Sezary in 1 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cristofoletti, C | 1 |
| Bresin, A | 1 |
| Picozza, M | 1 |
| Picchio, MC | 1 |
| Monzo, F | 1 |
| Helmer Citterich, M | 1 |
| Passarelli, F | 1 |
| Frezzolini, A | 1 |
| Scala, E | 1 |
| Monopoli, A | 1 |
| Cantonetti, M | 1 |
| Benucci, R | 1 |
| D'Atri, S | 1 |
| Caprini, E | 1 |
| Russo, G | 1 |
| Narducci, MG | 1 |
1 other study available for metformin and Erythroderma, Sezary
| Article | Year |
|---|---|
Blood and skin-derived Sezary cells: differences in proliferation-index, activation of PI3K/AKT/mTORC1 pathway and its prognostic relevance.
Topics: Biomarkers; Cell Line, Tumor; Cell Movement; Cell Proliferation; DNA Copy Number Variations; Humans; | 2019 |